Crown Bioscience

THE 3R LÄND Conference explores cutting-edge advancements in this ever-evolving field, and we’re thrilled to announce our Director of Scientific Engagement and Consultancy Nataliia Beztsinna will be in attendance. Schedule a meeting: hubs.la/Q047yq8V0

As we mark Brain Tumour Awareness Month, we’re proud to share our own contribution to advancing preclinical brain cancer research. Download the full poster to explore our research in more detail: hubs.la/Q047pTys0

In this webinar, Davy Ouyang, PhD, Senior VP of Innovation at Crown Bioscience, will discuss how integrated translational models - including 3D organoids and PDX - can support more predictive ADC evaluation & faster decision-making. hubs.la/Q047bchK0

In this article, Crown Bioscience CEO John Gu shares his leadership philosophy for managing a highly technical, incredibly smart, multicultural workforce. Read now the full Interview: hubs.la/Q046YBBq0

This blog post outlines the key advantages and disadvantages of humanized mouse models to help researchers determine the right starting point for a study. Read now: hubs.la/Q046JQsJ0

In this study, our experts shine a light on the complexity of the tumor microenvironment (TME) in the MC38 colorectal cancer syngeneic model, leveraging NanoString GeoMx® Digital Spatial Profiler (DSP) technology. hubs.la/Q046JJ890

In the final blog of our three-part series, we illustrate how phase 3 translational and clinical support turns preclinical discoveries into effective clinical interventions. Read now: hubs.la/Q046JCDN0

In this webinar, our Senior VP of Innovation Davy Ouyang, PhD, will explore advanced translational platforms optimized for ADC evaluation. Register your place: hubs.la/Q046y-bH0

In this article for Drug Discovery World, our Director of Scientific Engagement David Vallerand examines the technologies advancing cell and gene therapy drug discovery. Read now: hubs.la/Q046lpGk0

Meet us at the NextGen Biomed event where our team will be at Booth 11, ready to help share expertise to enhance your biologics drug discovery & development journey! Schedule a meeting today: hubs.la/Q046bTcH0

Join Crown Bioscience and three cutting-edge biotechs at our exclusive event. Learn the critical translation strategies that separate successful programs from failed ones. Reserve your seat now to be part of the conversation. hubs.la/Q045XYnM0

With the rise of complex modalities, refining preclinical evaluation is critical to improving clinical translation. Our very own Dean Campbell will be delivering a speaker session on PDX models in oncology research. Schedule a meeting: hubs.la/Q045RVHP0

今月開催のウェビナーでは、薬剤耐性モデリングが、耐性を克服できる、賢明な成功確度の高い治療戦略を推進する上で不可欠な研究エンジンである理由について詳しくご説明します。詳細およびご登録はこちら→ hubs.la/Q045Q1xc0 #オンコロジー #腫瘍学 #創薬技術 @crownbioscience

In this CrownCast episode, Crown Bioscience’s Benjamin Wilkin and Davy Ouyang explore how an integrated approach – combining advanced model systems with deep data science capabilities – is driving more predictive and efficient ADC development programs. hubs.la/Q045LqnT0

In an article brimming with firsthand insights, our CEO John Gu shares why adaptability, practical leadership, and customer-centricity has always been the signature of Crown Bioscience. Watch or read here: hubs.la/Q045x43h0 15-Minute Read: hubs.la/Q045x7lY0

March is Brain Tumor Awareness Month, highlighting groundbreaking research and promising advancements in the treatment of this cancer type. Find out more here: hubs.la/Q045mg0v0 1https://www.cancer.gov/types/brain/research

Integrating PDX and organoids can help researchers identify responsive tumor subsets, anticipate resistance, and strengthen translational confidence before clinical testing. Our very own Marianne Baillargeon explores more in this article: hubs.la/Q0454C810

In this on-demand webinar, Head of Cancer Pharmacology Preclinical Jessie Wang details how resistance modeling drives the development of more resilient, intelligent, and successful treatment strategies. hubs.la/Q044-g7L0

In the second of our three-part blog series, Crown Bioscience’s Bindi Doshi, PhD, outlines how robust efficacy testing – when coupled with comprehensive safety and ADME evaluation – provides a clear understanding of compound performance. Read now: hubs.la/Q044N6XG0

Join us in London and gain unprecedented access to proprietary insights from Crown Bioscience and three cutting-edge biotechs actively advancing novel therapeutic platforms. Reserve your seat now and be part of the conversation! hubs.la/Q044qqjD0